grant
Dissecting the immunomodulatory effects of NK cells on immune responses to cancer
Organization FRED HUTCHINSON CANCER CENTERLocation SEATTLE, UNITED STATESPosted 1 Sept 2024Deadline 31 Aug 2029
NIHUS FederalResearch GrantFY2025Activated Natural Killer CellAddressAffectAntigen-Presenting CellsAntitumor ResponseAssayB16F10BioassayBiological AssayCancersCell BodyCell Communication and SignalingCell Culture TechniquesCell ShapeCell SignalingCellsCheckpoint inhibitorChemotactic CytokinesClinicClinicalCombination immunotherapyCytokine Signal TransductionCytokine SignalingCytotoxic cellDataDendritic CellsDevelopmentDiseaseDisorderDisseminated Malignant NeoplasmEcologic SystemsEcological SystemsEcosystemEnsureFDA approvedFLT 3 LigandFLT3 ligandFLT3LFLT3LGFLT3LG geneFMS-Related Tyrosine Kinase 3 Ligand GeneFMS-Related Tyrosine Kinase-3 LigandGene set enrichment analysisHomologous Chemotactic CytokinesHumanHypoxiaHypoxicIL-15IL15IL15 ProteinImageImmuneImmune RegulatorsImmune checkpoint inhibitorImmune mediated therapyImmune responseImmunesImmunologically Directed TherapyImmunologyImmunomodulationImmunomodulatorsImmunotherapyIn VitroInfectionInfiltrationIntercrinesInterleukin-15Interleukin-15 PrecursorIntracellular Communication and SignalingIntrinsic factorK lymphocyteLigandsLymphatic cellLymphocyteLymphocyticLytotoxicityMGC9721MGF proteinMGSNF proteinMalignant MelanomaMalignant NeoplasmsMalignant TumorMeasuresMelanomaMelanoma MetastasisMelanoma patientMetastatic CancerMetastatic Malignant NeoplasmMetastatic MelanomaMiceMice MammalsModelingModern ManMolecularMurineMusNK CellsNatural Killer CellsOutcomeOutputOxygen DeficiencyPD-1 antibodyPD1 antibodyPathway interactionsPatientsPhenotypePopulationPopulation HeterogeneityProductionRNA SeqRNA sequencingRNAseqRegulationResearch ProposalsSIS cytokinesSTAT5STAT5ASTAT5A geneSTAT5a Transcription FactorSTK1-ligandSamplingShapesSignal PathwaySignal Transducer and Activator of Transcription 5ASignal TransductionSignal Transduction SystemsSignalingSliceStat5 proteinStat5a proteinStat5alpha proteinT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell responseT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-Cell ActivationT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyTechniquesTumor CellTumor ImmunityTumor PromotionVeiled CellsVeinsWorkaPD-1aPD1accessory cellactivate T cellsadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyanti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyanti-tumor immune responseanti-tumor immunityanti-tumor responseantiPD-1antitumor immunitybiological signal transductioncancer immunitycancer microenvironmentcell culturecell culturescheck point inhibitioncheckpoint inhibitionchemoattractant cytokinechemokinecombinatorial immunotherapycytokinecytotoxiccytotoxicitydevelopmentaldiverse populationsdual immunotherapyflk2 ligandflk2-flt3 ligandflt3 ligand proteinheterogeneous populationhost responseimagingimmune check point inhibitionimmune check point inhibitorimmune checkpoint inhibitionimmune microenvironmentimmune modulationimmune modulatorsimmune regulationimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic reactivity controlimmunomodulatoryimmunomodulatory moleculesimmunoregulationimmunoregulatorimmunoregulatoryimmunoregulatory moleculesimmunoresponseimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentin vivo Modellymph cellmalignancymammary gland factormammary gland-specific nuclear factormelanoma cancer modelmelanoma modelmelanoma tumor modelmouse modelmurine modelneoplasm/cancerneoplastic cellnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetpathwaypatient responsepatient specific responsepatients suffering from melanomapatients with melanomapopulation diversityresponseresponse to therapyresponse to treatmentresponsive patientsignal tranducer and activator of transcription 5spatial RNA sequencingspatial gene expression analysisspatial gene expression profilingspatial resolved transcriptome sequencingspatial transcriptome analysisspatial transcriptome profilingspatial transcriptome sequencingspatial transcriptomicsspatially resolved transcriptomicsspatio transcriptomicsstem cell tyrosine kinase 1 ligandsynergismtherapeutic T-cell platformtherapeutic responsetherapy responsethymus derived lymphocytetranscriptome sequencingtranscriptomic sequencingtranslational opportunitiestranslational potentialtreatment responsetreatment responsivenesstumortumor immune microenvironmenttumor microenvironmenttumor-immune system interactionsαPD-1αPD1
Description preview
PROJECT SUMMARY
Current immunotherapies, such as anti-PD-1 immunotherapy, have low objective responses in patients,
necessitating the development of novel therapies that boost immune responses to cancer and responses to these
treatments. Further, most immunotherapies in the clinic, anti-PD-1 immunotherapy included, predominantly act on
T cells.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click